tradingkey.logo

LivaNova PLC

LIVN
查看详细走势图
66.799USD
+0.039+0.06%
交易中 美东报价延迟15分钟
3.65B总市值
亏损市盈率 TTM

LivaNova PLC

66.799
+0.039+0.06%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+0.06%

5天

+4.05%

1月

+10.16%

6月

+62.41%

今年开始到现在

+8.56%

1年

+33.73%

查看详细走势图

TradingKey LivaNova PLC股票评分

单位: USD 更新时间: 2026-02-02

操作建议

LivaNova PLC当前公司基本面数据相对非常健康,最新ESG披露属于行业中等水平。增长潜力很大。当前估值合理,在医疗设备与耗材行业排名1/206位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价71.76。中期看,股价处于上升通道。近一个月,市场表现较强,技术面和基本面综合得分较高,较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。

LivaNova PLC评分

相关信息

行业排名
1 / 206
全市场排名
25 / 4529
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
看空

LivaNova PLC亮点

亮点风险
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
业绩高增长
公司营业收入稳步增长,连续3年增长22.67%
估值合理
公司最新PE估值-16.76,处于3年历史合理位
机构减仓
最新机构持股57.85M股,环比减少15.44%
乔尔·格林布拉特持仓
明星投资者乔尔·格林布拉特持仓,最新持仓市值8.54K

分析师目标

根据 11 位分析师
买入
评级
71.756
目标均价
+9.20%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

LivaNova PLC新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

LivaNova PLC简介

LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
公司代码LIVN
公司LivaNova PLC
CEOMakatsaria (Vladimir A)
网址https://www.livanova.com/
KeyAI